

# Bridging Gaps & Standardizing Care Among Head & Neck Cancer Patients Receiving Radiation

Maura Kenny, RN, BSN, OCN

Radiation Oncology Nurse

Hartford Healthcare Cancer Institute

[Maura.Kenny@hhchealth.org](mailto:Maura.Kenny@hhchealth.org)

Nicole Marcelino, RN, MSN, OCN

# Disclosures

- I have no relevant financial relationships with ineligible companies to disclose



# Session Objectives

The learner will:

- Identify different ways to promote interdisciplinary communication to enhance patient care in the HNC population
- Recognize positive interventions to address social risk factors in the HNC population



# Background

- HNC accounts for nearly 4% of all cancers in the United States
- About  $\frac{3}{4}$  is attributed to HPV (tobacco and excess alcohol consumption are the biggest risk factors for non HPV related) (“Head and neck cancers,” 2021)
- The Helen & Harry Gray Cancer Center treats approximately 70 HNC patients a year with radiation therapy



# First Day Goody Bags

“...almost 100% of those [patients] receiving radiation for head and neck cancer will develop oral mucositis” (“Mucositis,” 2019)




Personal photo

<b>Baking Soda</b>	¼ teaspoon	½ teaspoon	1 teaspoon
<b>Salt</b>	¼ teaspoon	½ teaspoon	1 teaspoon
<b>Water</b>	8 ounces	16 ounces	1 quart



# Head & Neck Rounds

Weekly interdisciplinary meeting



Nicole SLP, Diane RD, Maura RN, Moriah SW



# Inpatient HNC Active Treatment Order Set

## New Orders

Patient to receive supplements: three times a day - between meals; Order: Ensure Enlive, Vanilla, 8 oz

Effective now, Starting today at 1448, Until Specified

Patient to receive supplements: three times a day - between meals

Order: Ensure Enlive, Vanilla, 8 oz

### Daily weights

Routine, Daily, First occurrence today at 1447

### Nursing communication

Routine, Until discontinued, Starting today at 1444, Until Specified

Additional Information: Provide 0.9% NS and emesis basin for patient to rinse, gargle and spit every 2 hours or more often for comfort.

### Nursing communication

Routine, Until discontinued, Starting today at 1443, Until Specified

Additional Information: Offer oral care after meals and nightly with a soft toothbrush. Avoid alcohol based mouth rinses.

### triamcinolone (KENALOG) 0.1 % cream

Topical, 2 times daily, First dose today at 2100

Apply a thin film from jaw line to collarbone at a 1:1 ratio with aquaphor after radiation and nightly.

Site of application: Neck

### Inpatient consult to Nutrition Services

Consult reason: Adult Patient Profile risk screen result

### SLP eval and treat

Routine, Once, today at 1441, For 1 occurrence

Reason for Speech Therapy: Clinical/Bedside Swallow Eval & Treat

Clinical Indication: Difficulty swallowing, Aspiration risk



# Key Takeaways

- Forming a new partnership with the inpatient care team
- Identifying and addressing barriers HNC patients may face when starting treatment



Blaire inpatient RN, Emily inpatient RN, Maura RN, Nicole RN





# Contact Info

- Maura Kenny, RN, BSN, OCN  
Hartford Healthcare Cancer Institute  
Office phone: 860-972-4559  
[Maura.Kenny@hhchealth.org](mailto:Maura.Kenny@hhchealth.org)
- Nicole Marcelino, RN, MSN, OCN  
Hartford Healthcare Cancer Institute  
Office phone: 860-972-5718  
[Nicole.Marcelino@hhchealth.org](mailto:Nicole.Marcelino@hhchealth.org)



# References

- *Head and neck cancers*. National Cancer Institute. (2021, May 25). Retrieved February 28, 2023, from <https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet#what-are-cancers-of-the-head-and-neck>
- Messing, B. P., Ward, E. C., Lazarus, C., Ryniak, K., Kim, M., Silinonte, J., Gold, D., Thompson, C. B., Pitman, K. T., Blanco, R., Sobel, R., Harrer, K., Ulmer, K., Neuner, G., Patel, K., Tang, M., & Lee, G. (2018). Establishing a multidisciplinary head and neck clinical pathway: An implementation evaluation and audit of dysphagia-related services and outcomes. *Dysphagia*, 34(1), 89–104. <https://doi.org/10.1007/s00455-018-9917-4>
- *Mucositis*. ONS. (2019, November 26). Retrieved February 28, 2023, from [https://www.ons.org/pep/mucositis?display=pepnavigator&sort\\_by=created&items\\_per\\_page=50](https://www.ons.org/pep/mucositis?display=pepnavigator&sort_by=created&items_per_page=50)
- Yokota, T., Zenda, S., Ota, I., Yamazaki, T., Yamaguchi, T., Ogawa, T., Tachibana, H., Toshiyasu, T., Homma, A., Miyaji, T., Mashiko, T., Hamauchi, S., Tominaga, K., Ishii, S., Otani, Y., Orito, N., & Uchitomi, Y. (2021). Phase 3 randomized trial of topical steroid versus placebo for prevention of radiation dermatitis in patients with head and neck cancer receiving chemoradiation. *International Journal of Radiation Oncology\*Biophysics*, 111(3), 794–803. <https://doi.org/10.1016/j.ijrobp.2021.05.133>

